NCT06246422

Brief Summary

Adult patients undergoing laparoscopic cholecystectomy are at high risk to develop postoperative bleeding especially in the presence of severe adhesions. Local instillation of the antifibrinolytic (tranexamic acid) at the gall bladder bed may decrease the risk of bleeding. The aim of this study is to evaluate the role of topical administration of Tranexamic acid on gallbladder bed for prophylaxis against bleeding in cases of difficult dissection cases due to acute inflammation and dense adhesions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
91

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 11, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 13, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 13, 2022

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

January 30, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 7, 2024

Completed
Last Updated

February 24, 2025

Status Verified

February 1, 2025

Enrollment Period

1 year

First QC Date

January 30, 2024

Last Update Submit

February 20, 2025

Conditions

Keywords

gall bladderpostoperative bleedingtranexamic acid

Outcome Measures

Primary Outcomes (1)

  • Hematocrit concentration in the drain

    The level of hematocrit in the drain 6 h after surgery

    6 hours

Secondary Outcomes (2)

  • Hemoglobin level in the drain

    6 hours

  • Length of hospital stay.

    24 hours

Study Arms (2)

group A

EXPERIMENTAL

after careful hemostasis for the bleeding points in the liver bed received 500 mg of Tranexamic acid dissolved in 20 ml normal saline locally in the liver bed through the right port, then introduction of a piece of gauze to keep the drug in place for about 3 minutes and then remove it and inserting a drain and close it for one hour after finishing the operation.

Drug: Tranexamic Acid 500 MG

group B

EXPERIMENTAL

they also underwent the same procedure with routine care for hemostasis until there was no significant bleeding and then instillation of 20 ml normal saline in the gallbladder bed , then drain was inserted and closed for 1 hour the sameway as group A.

Drug: Normal saline

Interventions

Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed

group A

Local instillation of 20 ml normal saline in the gall bladder bed

group B

Eligibility Criteria

Age21 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Adult patients aged 21-60 years that underwent laparoscopic cholecystectomy with intra-operative difficult dissection due to adhesions or acute inflammation.

You may not qualify if:

  • Patients who will refuse participation in the study
  • Patients with bleeding disorders, clotting abnormalities, or on anticoagulants therapy.
  • Easy going operation that do not necessitate drain insertion.
  • major bleeding that could necessitate surgical intervention to control.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine

Al Fayyum, 63512, Egypt

Location

MeSH Terms

Conditions

Postoperative ComplicationsPostoperative Hemorrhage

Interventions

Tranexamic AcidSaline Solution

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsHemorrhage

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The participants and the investigator will be kept blinded by the aid of closed sealed envelops. The measurements will be collected by the aid of assistant resident who will not participating into the study and blinded to it.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Prospective study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

January 30, 2024

First Posted

February 7, 2024

Study Start

December 11, 2021

Primary Completion

December 13, 2022

Study Completion

December 13, 2022

Last Updated

February 24, 2025

Record last verified: 2025-02

Locations